These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12182866)

  • 1. 8-Aryl xanthines potent inhibitors of phosphodiesterase 5.
    Arnold R; Beer D; Bhalay G; Baettig U; Collingwood SP; Craig S; Devereux N; Dunstan A; Glen A; Gomez S; Haberthuer S; Howe T; Jelfs S; Moser H; Naef R; Nicklin P; Sandham D; Stringer R; Turner K; Watson S; Zurini M
    Bioorg Med Chem Lett; 2002 Sep; 12(18):2587-90. PubMed ID: 12182866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,3-bis(cyclopropylmethyl)xanthine.
    Buckle DR; Arch JR; Connolly BJ; Fenwick AE; Foster KA; Murray KJ; Readshaw SA; Smallridge M; Smith DG
    J Med Chem; 1994 Feb; 37(4):476-85. PubMed ID: 8120866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.
    Xia G; Li J; Peng A; Lai S; Zhang S; Shen J; Liu Z; Chen X; Ji R
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2790-4. PubMed ID: 15878277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors.
    Wang Y; Chackalamannil S; Hu Z; Boyle CD; Lankin CM; Xia Y; Xu R; Asberom T; Pissarnitski D; Stamford AW; Greenlee WJ; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
    Bioorg Med Chem Lett; 2002 Nov; 12(21):3149-52. PubMed ID: 12372521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of alkyl substituents of xanthine on phosphodiesterase isoenzymes.
    Miyamoto K; Sakai R; Kurita M; Ohmae S; Sanae F; Sawanishi H; Hasegawa T; Takagi K
    Biol Pharm Bull; 1995 Mar; 18(3):431-4. PubMed ID: 7550097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery of novel, potent and selective PDE5 inhibitors.
    Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
    Bioorg Med Chem Lett; 2001 Sep; 11(18):2461-4. PubMed ID: 11549447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and selective xanthine-based inhibitors of phosphodiesterase 5.
    Arnold NJ; Arnold R; Beer D; Bhalay G; Collingwood SP; Craig S; Devereux N; Dodds M; Dunstan AR; Fairhurst RA; Farr D; Fullerton JD; Glen A; Gomez S; Haberthuer S; Hatto JD; Howes C; Jones D; Keller TH; Leuenberger B; Moser HE; Muller I; Naef R; Nicklin PA; Sandham DA; Turner KL; Tweed MF; Watson SJ; Zurini M
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2376-9. PubMed ID: 17337182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation.
    Meskini N; Némoz G; Okyayuz-Baklouti I; Lagarde M; Prigent AF
    Biochem Pharmacol; 1994 Mar; 47(5):781-8. PubMed ID: 8135854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors.
    Ukita T; Nakamura Y; Kubo A; Yamamoto Y; Moritani Y; Saruta K; Higashijima T; Kotera J; Fujishige K; Takagi M; Kikkawa K; Omori K
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2341-5. PubMed ID: 12824030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus.
    Cortijo J; Bou J; Beleta J; Cardelús I; Llenas J; Morcillo E; Gristwood RW
    Br J Pharmacol; 1993 Feb; 108(2):562-8. PubMed ID: 8383567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases.
    Seftel AD
    Curr Pharm Des; 2005; 11(31):4047-58. PubMed ID: 16378510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
    Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
    Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development.
    Kayık G; Tüzün NŞ; Durdagi S
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):311-330. PubMed ID: 28150511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors.
    Asproni B; Murineddu G; Pau A; Pinna GA; Langgård M; Christoffersen CT; Nielsen J; Kehler J
    Bioorg Med Chem; 2011 Jan; 19(1):642-9. PubMed ID: 21087867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine(BL 191). I. Cyclic 3',5'-nucleotide phosphodiesterase (PDE) and the inhibitory effect of BL 191 on PDE in rat brain and heart.
    Hayashi S; Ozawa H
    Chem Pharm Bull (Tokyo); 1974 Mar; 22(3):587-93. PubMed ID: 4371104
    [No Abstract]   [Full Text] [Related]  

  • 16. Benzothiophene derivatives as phosphodiesterase 10A (PDE10A) inhibitors: Hit-to-lead studies.
    Kawamoto Y; Tomino M; Hiramatsu K; Oyama Y; Hayashi Y
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1419-1422. PubMed ID: 30952590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.
    Ukita T; Nakamura Y; Kubo A; Yamamoto Y; Moritani Y; Saruta K; Higashijima T; Kotera J; Takagi M; Kikkawa K; Omori K
    J Med Chem; 2001 Jun; 44(13):2204-18. PubMed ID: 11405657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5.
    Dan A; Shiyama T; Yamazaki K; Kusunose N; Fujita K; Sato H; Matsui K; Kitano M
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4085-90. PubMed ID: 16005625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective tracheal relaxation and phosphodiesterase-IV inhibition by xanthine derivatives.
    Miyamoto K; Kurita M; Ohmae S; Sakai R; Sanae F; Takagi K
    Eur J Pharmacol; 1994 May; 267(3):317-22. PubMed ID: 8088370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.
    Bauer U; Giordanetto F; Bauer M; O'Mahony G; Johansson KE; Knecht W; Hartleib-Geschwindner J; Carlsson ET; Enroth C
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1944-8. PubMed ID: 22321214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.